Latest Ratios: P/E Ratio -2.2x · EV/EBITDA N/A · ROE N/A. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.9B | $869M | $111M | $205M | $185M | $535M | $491M | — | — | — | — |
| Enterprise Value | $2.9B | $829M | $69M | $216M | $133M | $459M | $399M | — | — | — | — |
| P/E Ratio → | -2.19 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 567.10 | 193.76 | 12.09 | 11.73 | 15.18 | 127.57 | 1320.39 | — | — | — | — |
| P/B Ratio | — | — | — | — | 4.07 | 6.02 | 4.42 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 184.87 | 7.50 | 12.33 | 10.89 | 109.35 | 1071.91 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.7% | 33.7% | 100.0% | 100.1% | 140.1% | 100.0% | 1187.4% | 100.0% | 69.8% | 81.0% | 84.3% |
| Operating Margin | -2921.0% | -2921.0% | -1060.6% | -587.7% | -468.9% | -1242.6% | -7988.7% | -433.2% | -1040.1% | -320.8% | -137.8% |
| Net Profit Margin | -7587.8% | -7587.8% | -2002.7% | -631.8% | -445.6% | -1183.5% | -9037.4% | -431.9% | -1051.5% | -264.2% | -74.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -1642.8% | -80.8% | -49.6% | -44.1% | -58.7% | -53.5% | -34.6% | -18.0% |
| ROA | -184.9% | -184.9% | -195.4% | -119.0% | -45.6% | -38.0% | -34.3% | -44.2% | -43.6% | -28.0% | -12.9% |
| ROIC | — | — | — | — | -1506.6% | -279.0% | -209.8% | -356.0% | -397.5% | -185.4% | -60.4% |
| ROCE | -154.3% | -154.3% | -1106.2% | -196.2% | -61.9% | -46.5% | -35.4% | -56.2% | -51.0% | -39.5% | -28.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.76 | 0.11 | 0.09 | 0.00 | 0.04 | 0.01 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -1.15 | -0.86 | -0.83 | -0.86 | -0.88 | -0.92 | -0.68 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -4.05 | -4.05 | -14.10 | -20.21 | -80.85 | -388.55 | -494.30 | -10071.33 | -135.83 | -4306.62 | -1597.61 |
Net cash position: cash ($99M) exceeds total debt ($59M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.15 | 3.15 | 0.92 | 0.96 | 3.47 | 5.06 | 9.56 | 3.53 | 4.75 | 7.64 | 4.80 |
| Quick Ratio | 3.15 | 3.15 | 0.92 | 0.95 | 3.45 | 5.04 | 9.54 | 3.50 | 4.72 | 7.59 | 4.74 |
| Cash Ratio | 1.28 | 1.28 | 0.80 | 0.54 | 2.86 | 3.79 | 8.13 | 2.58 | 3.76 | 6.71 | 2.89 |
| Asset Turnover | — | 0.02 | 0.08 | 0.25 | 0.10 | 0.03 | 0.00 | 0.12 | 0.04 | 0.09 | 0.19 |
| Inventory Turnover | — | — | — | -0.06 | 2.67 | 2.59 | 2.64 | — | 2.36 | 2.61 | 3.15 |
| Days Sales Outstanding | — | 742.30 | 482.42 | 328.03 | 8.36 | 1008.41 | 47.10 | 33.54 | 1520.28 | 383.99 | 173.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $187M | $52M | $45M | $41M | $39M | $34M | $24M | $21M | $16M | $16M |
Clinical trial funding dependency
As reported in financial statements, Inventiva's price-to-sales ratio of 425.43x suggests that market participants are pricing the equity based on speculative future clinical success rather than current revenue, which remains negligible and highly volatile compared to the broader biotechnology sector's more established commercial-stage peers.
The astronomical P/S multiple indicates that investors are effectively ignoring traditional valuation metrics in favor of a 'real options' approach to the company's pipeline. This valuation implies that the market expects a significant de-risking event, likely tied to the NATiV3 trial, which would fundamentally alter the company's revenue profile.
Based on historical data, Inventiva's return on invested capital has consistently trended in negative territory, with the most recent figures showing a ROA of -82.8%, illustrating the company's inability to generate positive returns on the capital deployed into its research-heavy, non-commercial business model.
The persistent negative ROIC highlights that the company is currently a value-destroyer from a pure accounting perspective, which is typical for clinical-stage firms but warrants caution. Investors should monitor whether the company can achieve a pivot to positive returns once the lead candidate reaches the commercialization phase.
According to quarterly filings, the company's asset turnover ratio has remained near zero, reflecting the lack of commercial product sales and the reliance on R&D-driven milestones, which creates significant friction in the cash conversion cycle compared to more operationally mature healthcare entities in the sector.
The erratic nature of the cash conversion cycle, characterized by massive swings in accounts payable and receivable, suggests that operational efficiency is secondary to the timing of partnership-related cash inflows. This lack of predictable working capital management makes the company highly sensitive to liquidity shocks.
As indicated by the current ratio of 3.15 in 2025Q4, Inventiva maintains a superficial liquidity cushion, yet this figure is misleading given the high quarterly cash burn rate and the absence of consistent, recurring revenue streams to support ongoing clinical trial operations without external financing.
While the current ratio appears healthy on the surface, the underlying cash burn suggests that the company's runway is significantly shorter than the raw liquidity ratios might imply. The reliance on external capital markets to maintain this liquidity position remains a primary risk factor for shareholders.
Based on an analysis of the company's financial reporting, the most commonly misapplied metric is the gross margin, which, at -40.6% in 2025Q4, obscures the true economic reality of the business by conflating R&D-related service costs with the potential future profitability of the Lanifibranor asset.
Investors should avoid using gross margin as a proxy for product profitability, as it currently reflects accounting treatments for partnership collaborations rather than commercial manufacturing costs. A more appropriate focus would be the 'cash burn per clinical milestone' to better assess the company's true operational efficiency.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IVA stock.
Inventiva S.A.'s current P/E ratio is -2.2x. This places it at the 50th percentile of its historical range.
Based on historical data, Inventiva S.A. is trading at a P/E of -2.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Inventiva S.A. has 33.7% gross margin and -2921.0% operating margin.